Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

About this update from Kiora Pharmaceuticals, Inc.

[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases.","length":358,"tagName":"p"},{"type":"text","content":"Key fourth-quarter, full-year 2025, and recent corporate highlights include:","length":76,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2 randomized, controlled clinical trial in patients with advanced retinitis pigmentosa.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened the strategic global commercial network for KIO-301 through an option agreement with Senju Pharmaceutical Co. Ltd. covering key Asian markets with potential deal value of up to $110 million plus royalties, if exercised.","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced KIO-104 from regulatory clearance to patient dosing in KLARITY, a Phase 2 dose-escalating trial evaluating the treatment of macular edema due to retinal inflammation.","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended 2025 with $17.1 million in cash, cash equivalents, and short-term investments, plus $3.5 million in receivables consisting of $1.5 million in collaboration receivables, $1.0 million in tax receivables, and $1.0 million in research credit and other receivables.","length":266,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported fourth-quarter and full-year 2025 net cash used in operating activities of $2.2 million and $10.0 million, respectively.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Identified the potential for platform expansion of KIO-300 as an ion-channel modulator through a preclinical ex vivo proof of concept study in the treatment of epilepsy.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Based on current operating plans, expects existing cash, cash equivalents, and short-term investments to fund operations into late 2027, beyond anticipated topline data readouts for ABACUS-2 and KLARITY.","length":203,"tagName":"p"}]}],"tagName":"ul","bulle...

More updates from Kiora Pharmaceuticals, Inc.